Weiss hearing on Tamcocor and Enkaid
Executive Summary
Rep. Weiss' (D-N.Y.) House Intergovernmental Relations Subcommittee tentatively plans hearing for April 10 on the marketing of Riker's Tambocor (flecainide) and Bristol-Myers Squibb's Enkaid (encainide). FDA has restricted the "1C" anti- arrhythmics for use only in life-threatening arrhythmias following the results of the Cardiac Arrhythmia Suppression Trial that found that the two drugs caused almost a four-fold increase in mortality. Reportedly, FDA's Division of Drug Advertising & Labeling is preparing testimony regarding the marketing of the two anti-arrhythmics.